저자들은 부인과 악성종양에서 GnRH analogue인 D-Trp-6-LHRH 투여의 효용성을 알아보기 위하여 자궁경부암, 융모상피암 및 난소암 환자에서 투여전과 투여후 연속적으로 FSH, LH의 혈청값을 측정하였고, CEA, β-hCG, SP1 및 CA 125 같은 종양표지물 수치의 변화를 관찰한 바 다음과 같은 결론을 얻었다. 1. 부인과 악성종양 환자에서 D-Trp-6-LHRH 투여전에 비해 투여후 1주일에 성선자극호르몬갑이 유의하게 감소되었다. 2. CEA의 기초값이 5ng/ml 이상이었던 자궁경부암 환자에서는 D-Trp-6-LHRH 투여후 1주일에 성선자극호르몬의 감소와 일치하여 CEA값도 감소되는 경향을 보였다. 3. 융모상피암 환자와 난소암 환자에서는 D-Trp-6-LHRH 투여에 의한 β-hCG, Sp1 및 CA 125의 변화는 관찰할 수 없었다.

There are several reports that hormone and antibhormone treatment has a role in the therapy of malignant tumors arising from hormone-dependent tissues such as breast, endometrium, ovary, and prostate. Hormone-related methods of therapy aim at the elemination of endogenous hormones that may stimulate tumor growth, inteference with the action of the endogenous hormones and specific cytotoxic or cytostatic effects for cancer cells. GnRH analogues eliminate the endogenous hormones by suppression of hormone production via inhibition of pituitary secretions. The uterine cervix is a part of the hormonally regulated female genital tract and the presence of cytoplasmic and nuclear estrogen and progesterone receptor in cervical cancer have been reported. Also, there are several reports that antiestrogenic agents have some growth inhibitory effects in cervical cancer and in cell lines derived from the cervical cancer. These results suggest that the growth inhibitory effect of antiestrogens is mediated through binding to estrogen receptors and so the rationale for the clinical use of these drugs. The mechanism of action of GnRH analogues is known as down-regulation of GnRH receptors of the pituitary by binding much more strongly to those receptors than natural GnRH. Consequently, the GnRH receptors become refractory and desensitized, their number decreases leading to a very low output of FSH and LH and a decreased estrogen level in plasma. There are several reports that GnRH analogues have some growth inhibitory effects in prostate cancer, ovarian cancer, endometrial cancer, breast cancer and several hormone dependent benign diseases. But, there are no studies dealing with the effects of the GnRH agonist on cervical cancer and choriocarcinoma. So, present study was carried out to investigate the growth inhibitory effects of GnRH analogues on the basis of presence of estrogen and progesterone receptor in cervical cancers and choriocarcinomas including ovarian cancers. The results were as follow : 1. FSH and LH values were significantly reduced one week after administaration of D-Trp-6-LHRH in patients with cervical cancer,ovarian cancer and choriocarcinoma. 2.There was no statistical difference between baseline CEA value and the CEA values one week after administaration of D-Trp-6-LHRH in patients with cervical cancer,but we have observed the considerable reduction of CEA values correspondently to the decrease of gonadotrophons in 6 cases which CEA values were above 5 ng/ml. 3.We could not have observed the significant changes of B-hCG level and SP1 levels in patients with choriocarcinoma and CA 125 in patients with ovarian cancer by administration of D-Trp-6-LHRH.